tbuckley/cabot-search huggingface dataset:
Continuing Medical Education
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"ATHLETIC STRENUOSITY"
Authors: John W. Shuman
Journal: JAMA (1925)

<h3>To the Editor:</h3> —Your editorial (The Journal, July 25, p. 270) advocating "graded constant calisthenics, exercise, athletics and outdoor life" and decrying "competitive athletics" reads as if written by a nonathletic pacifist, who graced the bleachers (if he attended athletics at all) during and after his college life and who takes his exercises from a phonograph, radio or sport page. "Care-of-the-body," "keeping-fit" and "survival of the fittest" are all hashed-over, time-honored subjects. The spirit of progress demands speed and endurance. Monotony and tedious routine do not yield happiness (the ultimate aim of life) to the average human being; variety, competition, victory and defeat do. The trained man in medicine who was a trained athlete finds few instances wherein athletics strenuously done produced any ill effects, especially in reference to the heart. On the other hand, he does find many persons, especially women (who were never athletes in any sense of
Is FISH Painting an Appropriate Biological Marker for Dose Estimates of Suspected Accidental Radiation Overexposure? A Review of Cases Investigated in France from 1995 to 1996
Authors: Irene Sorokine-Durm, Valerie Durand, Annie Le Roy, Nathalie Paillole, Laurence Roy, Philippe Voisin
Journal: Environmental Health Perspectives (1997)
LAW &amp;amp; MEDICINE
Authors: Edwin J. Holman
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COMMISSIONS ON PRESCRIPTIONS.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Management of early cancer of the breast. Report on an international multicentre trial supported by the Cancer Research Campaign.
Authors: J Wc1 3bg P N Maton, J Pollard
Journal: BMJ (1976)

In the largest controlled clinical study so far undertaken on the management of early cancer of the breast in women the results of a radical regimen (simple mastectomy and radiotherapy) were compared with those of a conservative policy (simple mastectomy alone). The study included enough patients (2268) to ensure that small but significant differences between the two treatments would emerge. With a five-year follow-up there was no evidence that routine postoperative radiotherapy was harmful or that it conferred further benefit as regards survival or distant recurrence. Radiotherapy did, however, reduce the incidence of local recurrence. Neither form of treatment can counter occult disease far from the breast that is present at the time of initial treatment, which probably accounts for the high death rate from breast cancer, but the results of the study would support the view that conservative primary treatment and subsequent adjuvant chemotherapy may be the treatment of choice in future.
Whither biomedical research?
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
Authors: Evan Y. Yu, David Laidley, Frederic Pouliot, Stephan Probst, Robert Sabbagh, Giuseppe Esposito, Fred Saad, A. Oliver Sartor
Journal: Journal of Clinical Oncology (2020)

TPS5596 Background: PSMA is a transmembrane glycoprotein expressed in normal human prostate epithelium at low levels, but highly upregulated in metastatic prostate cancer (PC). 18 F-DCFPyL is a novel PSMA-targeted PET imaging agent that has shown highly promising diagnostic performance for detection of metastatic disease, with potential to identify disease amenable to theranostic targeting. 1095 is a novel PSMA-targeted small molecule that binds to the extracellular domain of PSMA selectively with high affinity. The complex is internalized, allowing the beta emitter, I-131, to kill PC cells. Methods: ARROW is an open-label, randomized (2:1) trial of enza plus 1095 or enza alone in pts with progressive mCRPC who previously received abi. ~120 pts (80: 1095 + enza; 40: enza alone) will be treated at ~40 sites in the US and Canada. Eligible male pts must be at least 18 yo with metastatic disease documented by bone scan or soft tissue lesions measurable per RECIST 1.1 on CT/MRI, be PSMA-avid as determined by 18 F-DCFPyL PET/CT, have evidence of biochemical or radiographic progression on abi, and be ineligible for or refuse to receive chemotherapy. Pts will receive enza (prescribed per approved labeling) with or without 1095 (100 mCi dose, followed by up to 3 additional dose(s) administered at least 8 weeks apart, as determined by dosimetry evaluation and occurrence of dose-limiting events). The primary objective is to determine the efficacy of 1095 plus enza compared to enza alone, based on PSA response (confirmed PSA decline ≥50%) rate according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria. Additional objectives include objective response rate based on PCWG3-modified RECIST 1.1, progression-free survival (PFS) defined as the first occurrence of radiographic progression (PCWG3-modified RECIST 1.1), unequivocal clinical progression, or death from any cause, duration of response, overall survival, and the safety and tolerability of 1095 radioligand therapy. Clinical trial information: NCT03939689 .
Urea-cycle enzymes in liver disease
Authors: H. Brown
Journal: JAMA (1967)

Enzymes catalyzing urea synthesis are of great importance because this is the primary pathway for nitrogen excretion in humans. Of equal importance is the fact that intermediates formed in the urea cycle enter into almost every known metabolic pathway. The urea-cycle enzymes are widely distributed in the plant and animal kingdom, but it is the five known hepatic enzymes with which we are concerned here.<sup>1</sup>The enzymes are carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), argininosuccinic acid synthetase, argininosuccinase, and arginase. They may be isolated in very pure form from liver homogenates and measured quantitatively. In practice, however, activity measurements in liver homogenates are used as an indication of amount of enzymes present. Through the action of the first urea-cycle enzyme, CPS, the metabolite carbamyl phosphate is formed from the union of ammonia, carbon dioxide, and adenosine triphosphate (ATP) (Figure). Carbamyl phosphate plays a key role at a critical
The Foundation of Health. A Manual of Personal Hygiene for Students.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leading Cases
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.
Authors: Michael J. Morris, Celestia S. Higano, Howard I. Scher, Christopher Sweeney, Emmanuel S. Antonarakis, Daniel H. Shevrin, Charles J. Ryan, Yohann Loriot, Karim Fizazi, Neeta Pandit-Taskar, Jose E. Garcia-Vargas, Kari Lyseng, Marianne Bloma, Jorge A. Carrasquillo
Journal: Journal of Clinical Oncology (2015)

5012 Background: Ra-223 is an approved α-emitter that prolongs survival in CRPC with symptomatic bone mets. We presented data from a phase 1/2a study of safety and antitumor effects of Ra-223 + D vs D alone showing that Ra-223 + D is safe and well tolerated (ESMO 2014). Here we report the effect of Ra-223 + D vs D on bALP and PSA dynamics. Methods: D-eligible pts with progressing CRPC and ≥ 2 bone mets received (2:1) Ra-223 (50 kBq/kg q 6 wk × 5) + D (60 mg/m2 q 3 wk × 10) or D (75 mg/m2 q 3 wk with a step-down option to 60 mg/m2). bALP and PSA were recorded q 3 wk during the first 6-wk cycle, then q 6 wk and q 3 wk, respectively, and analyzed at a central laboratory. Changes in both markers are described by the % of pts whose best responses were ≥ 30%, > 50%, and > 80% declines from baseline (3 wk post last D injection); pts with elevated baseline bALP ( ≥ 21 µg/L) were included for bALP analysis. bALP to below upper limit of normal (ULN) was also recorded, regardless of % decline. Results: 46 pts (33 Ra-223 + D vs 13 D alone) were enrolled. As of January 2015, 24 (Ra-223 + D) vs 5 (D) pts had all planned injections. Median (range) baseline PSA was 99 µg/L (3-1000) for Ra-223 + D pts and 43 µg/L (4-1042) for D pts. The table shows maximal changes in PSA and bALP levels from baseline. No pt had a bALP increase. Pts continue in follow-up (to 12 mo after first injection) for safety and progression. Conclusions: Ra-223 + D appears to favorably impact post-treatment declines in PSA and bALP and to be particularly effective at normalizing bALP levels vs D alone. Clinical benefits of such changes in serum markers require validation in larger prospective studies. Clinical trial information: NCT01106352. Change from baseline, n (%) PSA bALP* Ra-223 + D N = 33 D N = 13 Ra-223 + D N = 23 D N = 11 Any increase 3 (9) 4 (31) 0 (0) 0 (0) Best responses, decreases < 30% 4 (12) 1 (8) 0 (0) 0 (0) ≥ 30% 26 (79) 8 (62) 23 (100) 11 (100) > 50% 21 (64) 7 (54) 22 (96) 9 (82) > 80% 10 (30) 4 (31) 9 (39) 2 (18) *Pts with baseline bALP > ULN (> 21 μg/L). N/A = not applicable.
THE PARATHYROID HORMONE—A WARNING
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Latin Usage
Authors: CONSTANTINE H. MAKRIS
Journal: JAMA (1976)

<h3>To the Editor.—</h3> An article with a Latin title "Morituri Te Salutamus" (233:1356, 1975) deserves, I think, correct Latin. However, I am afraid Dr Goldman's Latin is a little rusty in several points: The title, as he had put it, was used by the gladiators to Caesar ("[We], who will die, salute thee, [Caesar]"); since he means to salute the gladiators, it should have been Morituri vos salutamus. In his phrase Ave et atque non vale, either the "et" or the "atque" is repetitious since "et" means the same as "atque." The classical version Ave atque vale meant "Hail and be healthy" (not "hail and farewell"), unless one would use "farewell" not with the meaning of separation, but as "fare [be] well." Ave atque vale, Doctore Leone Aure!
Health Research and the World Humanitarian Summit—Not a Thousand Miles Apart
Journal: PLoS Medicine (2016)

marks the first World Humanitarian Summit (WHS), convened in Istanbul by United Nations Secretary-General Ban Ki-Moon following three years of preparatory consultations [1].In an effort to resolve current humanitarian crises and avert future ones, the event aims to bring together heads of state, leaders of crisis-affected communities, representatives from industry, multilateral and nongovernment organizations, and other groups involved in humanitarian crises.Remarkably, the same dates bring a key meeting for another UN agency: the 69th World Health Assembly, through which member states govern the World Health Organization (WHO), meets May 23-28 in Geneva, more than 1,000 miles away.Health crises are both cause and consequence of humanitarian crises.As part of the WHS consultation process, WHO has emphasized that "[t]he health and well-being of affected populations is the ultimate goal of humanitarian action" [2].The Secretary-General's report for the WHS, which includes the five-section Agenda for Humanity, describes the present situation in cataclysmic terms that include global threats to health:
Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)
Authors: Jatin J. Shah, Lei Feng, Sheeba K. Thomas, Donna M. Weber, Michael Wang, Brandi Hilder, Raymond Alexanian, Robert Z. Orlowski
Journal: Blood (2013)
Reply
Authors: C. Long, R. Motley, P. Holt
Journal: British Journal of Dermatology (1995)

Journal Article Reply Get access C. Long, C. Long Department of Dermatology, University Hospital of Wales, Heath Park, Cardiff, U.K. Search for other works by this author on: Oxford Academic Google Scholar R. Motley, R. Motley Department of Dermatology, University Hospital of Wales, Heath Park, Cardiff, U.K. Search for other works by this author on: Oxford Academic Google Scholar P. Holt P. Holt Department of Dermatology, University Hospital of Wales, Heath Park, Cardiff, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 133, Issue 3, 1 September 1995, Pages 492–493, https://doi.org/10.1111/j.1365-2133.1995.tb02689.x Published: 01 September 1995
Exploding Bottles
Authors: Donald R. Moyes, Billy F. Andrews
Journal: JAMA (1962)

<h3>To the Editor:—</h3> There are few areas in the field of medicine where the old adage, "an ounce of prevention is worth a pound of cure," is more applicable than in the realm of accidents. There is a bizarre type of accident which, though not widely publicized, is probably not an infrequent occurrence, particularly during the warm seasons and in tropical climates. Seven cases of injuries resulting from fragments of exploding bottles containing carbonated beverages recently came to our attention while we were stationed at a military hospital in Puerto Rico: Penetrating injury of the right eye, requiring enucleation, in a 23-year-old male. Deep, 7-cm. laceration of the right leg in a 6-year-old female, extending to anterior surface of tibia. Laceration of the left wrist in an 11-year-old male. Laceration of the left leg in a 40-year-old male who was standing 15 feet from the exploding